rethinkTHC Search
Menu
Study breakdown

Medical cannabis states had lower opioid prescription rates in adults under 55

Cross SectionalModerate evidence
The takeaway

States with medical cannabis laws had significantly lower opioid prescription rates among privately insured adults under 55, but not among those 55-64, and recreational cannabis or decriminalization laws showed no association.

Policymakers, pain management clinicians, and researchers studying the opioid-cannabis relationship.

44% lower opioid prescriptions in 18-25 year-olds in medical cannabis states

What the researchers found

In states with medical cannabis laws, opioid prescription rates (>30-day and >90-day) were significantly lower for adults aged 18-54 (aORs ranging from 0.56 to 0.77). The association was not significant for ages 55-64. Recreational use and decriminalization laws showed no significant association with opioid prescriptions in any age group.

Why it matters

The opioid crisis has driven interest in whether cannabis access could reduce opioid dependence. This study provides evidence that medical cannabis laws specifically (not recreational or decriminalization) are associated with lower opioid prescribing in younger adults.

The numbers in context

Medical cannabis states: >30-day opioid aOR = 0.56 (ages 18-25), 0.67 (26-35), 0.67 (36-45), 0.76 (46-54). All p < 0.0001. Not significant for ages 55-64. No association with recreational or decriminalization laws.

How the study worked

Cross-sectional analysis of the 2016 Clinformatics Data Mart, a nationwide commercial insurance database. Multilevel multivariable analysis compared opioid prescribing patterns across states with different cannabis law stringencies, stratified by five age groups.

What this study cannot tell us

Cross-sectional design; cannot establish causation. Only privately insured adults included. State-level confounders (pain management culture, prescribing policies) could explain differences. Cannabis use itself was not measured.

How to read the evidence

Moderate: large nationwide insurance database with multilevel analysis, but cross-sectional and ecological design.

When this study was published

Published in 2019.

The bigger picture

The finding that only medical cannabis laws (not recreational or decriminalization) showed an association suggests something specific about the medical framework matters, possibly clinical involvement or insurance coverage.

Questions still open

  • Why did the association disappear in adults 55-64? Are older adults less likely to substitute cannabis for opioids? Would similar patterns emerge in Medicaid or Medicare populations?

Common questions

Does this mean cannabis replaces opioids?
The study found an association between medical cannabis laws and lower opioid prescribing, but it did not measure individual-level substitution. Other factors in states that adopt medical cannabis laws could contribute.
Why only medical cannabis and not recreational?
The authors did not definitively explain this, but it may relate to the medical framework encouraging physician involvement, or the types of patients who seek medical cannabis being the same ones who might otherwise receive opioid prescriptions.

Read the original research

Association between cannabis laws and opioid prescriptions among privately insured adults in the US.

Preventive medicine, 125, 62-68

Citation

Raji, Mukaila A; Abara, N Ogechi; Salameh, Habeeb; Westra, Jordan R; Kuo, Yong-Fang. (2019). Association between cannabis laws and opioid prescriptions among privately insured adults in the US.. Preventive medicine, 125, 62-68. https://doi.org/10.1016/j.ypmed.2019.05.012